Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

NanoString Technologies Inc (NASDAQ:NSTG)

Delayed Data
As of Nov 25
 +0.48 / +3.20%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

NanoString Technologies, Inc. develops, manufactures and sells robust, intuitive products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue. Its nCounter Analysis System directly profiles hundreds of molecules simultaneously using a novel barcoding technology that is powerful enough for use in research, simple enough for use in clinical laboratories worldwide. The company operates its business through two Segments: Life Sciences and Diagnostics. The Life Sciences segment provides instruments, consumables and services for efficiently profiling the activity of hundreds of genes from a single tissue sample. The Diagnostics segment provides molecular diagnostic kits to pathology labs enabling complex molecular testing on a decentralized basis. NanoString Technologies was founded by Amber Ratcliffe, Krassen Dimitrov and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.

Contact Information

NanoString Technologies, Inc.
530 Fairview Avenue North
Seattle Washington 98109
P:(206) 378-6266
Investor Relations:



Mutual fund holders8.03%
Other institutional49.23%
Individual stakeholders38.30%

Top Executives

Robert Bradley GrayPresident, Chief Executive Officer & Director
Wayne D. BurnsSenior Vice President-Operations & Administration
James Algot JohnsonChief Financial Officer
Joseph M. BeechemSenior Vice President-Research & Development
Alessandra CesanoChief Medical Officer